Treatment of Orthostatic Hypotension

Definition and Diagnosis

• The European Society of Cardiology recommends testing for orthostatic hypotension by measuring blood pressure after 5 minutes of sitting/lying and then 1 and/or 3 minutes after standing 1, 2

Non-Pharmacological Management

• The American Heart Association suggests increasing fluid and salt intake if not contraindicated by other conditions, as well as implementing physical counter-maneuvers, such as leg-crossing, stooping, squatting, and tensing muscles, to help manage orthostatic hypotension 3, 4
• The European Society of Cardiology recommends gradual staged movements with postural change and advising acute water ingestion (≥480 mL) for temporary relief, with peak effect occurring 30 minutes after consumption 3, 4
• The American Diabetes Association suggests recommending smaller, more frequent meals to reduce post-prandial hypotension, and encouraging physical activity and exercise to avoid deconditioning 5, 6

Pharmacological Management

• The American College of Cardiology recommends considering pharmacological treatment when non-pharmacological measures fail to adequately control symptoms, with the therapeutic goal of minimizing postural symptoms rather than restoring normotension 3, 4, 5
• The European Society of Cardiology suggests using midodrine, fludrocortisone, or droxidopa as first-line medications, with dosing and monitoring guidelines to minimize adverse effects 3, 4

Special Considerations

• The American Heart Association recommends considering long-acting dihydropyridine calcium channel blockers or RAS inhibitors as first-line therapy for patients with both hypertension and orthostatic hypotension 7
• The American Diabetes Association suggests assessing for cardiovascular autonomic neuropathy in diabetic patients with orthostatic hypotension, and considering α-lipoic acid for painful diabetic neuropathy and potentially beneficial for autonomic function 4, 5

Treatment of Orthostatic Hypotension

Non-Pharmacological Management

• Elevating the head of the bed during sleep can help prevent supine hypertension, as recommended by the American Heart Association, in patients with orthostatic hypotension 8

Management of Orthostatic Hypotension

Pharmacological Management

• The American Diabetes Association recommends fludrocortisone as a first-line medication for orthostatic hypotension, with an initial dose of 0.05–0.1 mg daily and individual titration to 0.1–0.3 mg daily, acting through sodium retention and vessel wall effects, and monitoring for adverse effects such as supine hypertension, hypokalemia, congestive heart failure, and peripheral edema 9
• For non-responders to monotherapy, consider combination therapy with midodrine and fludrocortisone, as recommended by the Diabetes/Metabolism Research and Reviews 10, 9

Orthostatic Hypotension Management

Diagnostic Evaluation and Reversible Causes

• The American Heart Association recommends evaluating for reversible causes of orthostatic hypotension, including medication effects, volume depletion, neurogenic causes, and endocrine disorders, to guide treatment 11

Non-Pharmacological Management

• The American College of Cardiology suggests increasing fluid intake to 2-3 liters daily and salt consumption to 6-9g daily, if not contraindicated, to help manage orthostatic hypotension 11
• Physical counter-maneuvers, such as leg crossing, muscle tensing, squatting, and stooping, can be implemented during symptom onset to help alleviate orthostatic hypotension symptoms 11
• Compression garments, including thigh-high and abdominal compression, are recommended to help reduce symptoms of orthostatic hypotension 11
• Acute water ingestion of ≥480 mL can provide temporary relief, with peak effect occurring 30 minutes after consumption, for patients with orthostatic hypotension 11

Pharmacological Management

• Midodrine, an alpha-1 agonist, is a first-line medication for orthostatic hypotension, with an initial dose of 2.5-5mg three times daily, and can increase standing systolic BP by 15-30 mmHg for 2-3 hours 11
• Fludrocortisone, a mineralocorticoid, is a first-line medication for orthostatic hypotension, with an initial dose of 0.05-0.1mg daily, and works by increasing plasma volume 11
• Droxidopa can improve symptoms in neurogenic orthostatic hypotension due to Parkinson's disease, pure autonomic failure, and multiple system atrophy, and may reduce falls 11

Special Considerations

• Avoid taking the last dose of midodrine after 6 PM to prevent supine hypertension during sleep 11
• Regular monitoring for adverse effects, especially supine hypertension with pressor agents and electrolyte abnormalities with fludrocortisone, is essential for patients with orthostatic hypotension 11

Orthostatic Hypotension Management

Causes and Risk Factors

• Drug-induced autonomic failure is the most frequent cause of orthostatic hypotension, with diuretics and vasodilators being the most important culprits, according to the European Society of Cardiology 12
• Alcohol can cause orthostatic intolerance through both direct acute actions on the central nervous system and central volume depletion, as reported by the European Society of Cardiology 12

Non-Pharmacological Interventions

• Discontinuation or modification of culprit medications is the first-line approach to managing orthostatic hypotension, as recommended by the European Heart Journal 12
• Patient education on gradual positional changes and avoiding precipitating factors is crucial for management, according to the American Diabetes Association 13
• Physical countermeasures such as leg crossing, stooping, squatting, and tensing muscles can help manage symptoms, as suggested by the American Diabetes Association 13
• Increased fluid and salt intake (if not contraindicated) helps maintain central volume, as recommended by the American Diabetes Association 13
• Elastic garments over the legs and abdomen can reduce venous pooling, according to the American Diabetes Association 13
• Head-up bed position during sleep helps prevent supine hypertension, as suggested by the American Diabetes Association 13
• Smaller, more frequent meals can reduce post-prandial hypotension, as reported by the American Diabetes Association 14
• Physical activity and exercise should be encouraged to avoid deconditioning, which worsens orthostatic intolerance, according to the American Diabetes Association 14 and 15

Pharmacological Interventions

• Midodrine is an FDA-approved peripheral selective α1-adrenergic agonist that exerts a pressor effect through arteriolar and venous constriction, as reported by the American Diabetes Association 13
• Fludrocortisone acts through sodium retention and vessel wall effects, according to the American Diabetes Association 13
• Droxidopa is FDA-approved for the treatment of orthostatic hypotension, as reported by the American Diabetes Association 14 and 15
• Erythropoietin can be considered for patients with anemia and severe autonomic neuropathy, as suggested by the American Diabetes Association 13
• Desmopressin acetate may correct nocturnal polyuria and morning orthostatic hypotension, according to the American Diabetes Association 13
• Shorter-acting antihypertensives at bedtime may help manage supine hypertension, as reported by the American Diabetes Association 14 and 15

Treatment Goals and Monitoring

• Treatment goals should focus on minimizing postural symptoms rather than restoring normotension, as recommended by the American Diabetes Association 13 and the American Heart Association 15
• Balance the benefits of increasing standing blood pressure against the risk of worsening supine hypertension, according to the American Diabetes Association 13
• Avoid medications that can exacerbate orthostatic hypotension when possible, including psychotropic drugs, diuretics, and α-adrenoreceptor antagonists, as suggested by the European Society of Cardiology 12 and the American Diabetes Association 13

Treatment of Refractory Orthostatic Hypotension

Introduction to Pyridostigmine

• Pyridostigmine is beneficial for treating refractory orthostatic hypotension in elderly patients who have not responded to other treatments, with fewer side effects than alternatives like fludrocortisone, as recommended by the American College of Cardiology 16

Clinical Guidelines Support

• According to the 2017 ACC/AHA/HRS guidelines, pyridostigmine may be beneficial in patients with syncope due to neurogenic orthostatic hypotension who are refractory to other treatments, with a favorable side effect profile 16
• The European Society of Cardiology recommends testing for orthostatic hypotension before starting or intensifying any blood pressure-lowering medication in elderly patients, and for patients aged ≥85 years with hypertension, long-acting dihydropyridine CCBs or RAS inhibitors are preferred first-line agents if antihypertensive therapy is needed 17

Side Effect Profile

• Common side effects of pyridostigmine include nausea, vomiting, abdominal cramping, sweating, salivation, and urinary incontinence, which are generally manageable 16

Treatment Algorithm

• When first-line treatments are ineffective, pyridostigmine may be considered, with dosing starting at low levels and titrating based on response, as outlined in the treatment algorithm for refractory orthostatic hypotension in elderly patients 16

Management of Orthostatic Hypotension

Rationale for Medication Adjustment

• The European Society of Cardiology (ESC) recommends that for patients with orthostatic hypotension, it is essential to switch BP-lowering medications that worsen orthostatic hypotension to an alternative therapy rather than simply reducing the dose 18

Medication-Specific Considerations

• RAS blockers are not recommended for patients with orthostatic hypotension due to their vasodilatory effects that can exacerbate postural blood pressure drops 18

Alternative Management Strategies

• Non-pharmacological approaches should be implemented as first-line treatment for orthostatic hypotension, including smaller, more frequent meals to reduce post-prandial hypotension 19
• Droxidopa is also FDA-approved for neurogenic orthostatic hypotension 19

Monitoring and Follow-up

• The therapeutic goal should be to minimize postural symptoms rather than to restore normotension 19
• Testing for orthostatic hypotension should be performed by measuring BP after 5 minutes of sitting/lying and then 1 and/or 3 minutes after standing 18

Orthostatic Hypotension Management

Non-Pharmacological and Pharmacological Interventions

• Elevating the head of the bed (10°) during sleep can help prevent nocturnal polyuria, maintain better fluid distribution, and ameliorate nocturnal hypertension, as recommended by the European Society of Cardiology 20
• Fludrocortisone, a mineralocorticoid, stimulates renal sodium retention and can be used to treat orthostatic hypotension, with an initial dose of 0.05-0.1mg daily, as noted by the European Heart Journal 20

Management of Postural Hypotension

Medication Management

• The European Society of Cardiology recommends switching BP-lowering medications that worsen orthostatic hypotension to alternative therapy, and discontinuing or significantly reducing ACE inhibitors like perindopril until symptoms resolve in patients with postural hypotension 21
• Consider stopping calcium channel blockers like lercanidipine temporarily, as they can be reintroduced cautiously if blood pressure control becomes necessary 22

Non-Pharmacological Management

• Increase fluid intake to 2-3 liters daily, unless contraindicated by heart failure, to help manage postural hypotension 23
• Increase salt intake to 6-9g daily, if not contraindicated, to help manage postural hypotension 23
• Elevate the head of bed by 10 degrees during sleep to prevent nocturnal polyuria and maintain favorable fluid distribution 23
• Teach leg crossing, squatting, and muscle tensing during symptomatic episodes to help manage postural hypotension 23
• Use compression garments, such as waist-high compression stockings and abdominal binders, to reduce venous pooling 23
• Eat smaller, more frequent meals to reduce post-prandial hypotension 23, 21

Pharmacological Treatment

• Fludrocortisone 0.1mg once daily is the recommended first-line pharmacological treatment, acting through sodium retention and vessel wall effects 23
• Midodrine 2.5-5mg three times daily can be used as a second-line agent if fludrocortisone is insufficient 23

Monitoring and Safety

• Measure blood pressure after 5 minutes lying/sitting, then at 1 and 3 minutes after standing, to document orthostatic changes, and monitor for both symptomatic improvement and development of supine hypertension 24
• The treatment goal is minimizing postural symptoms, not restoring normotension, and the risk of falls and injury from postural hypotension must be balanced against cardiovascular protection 24
• Reassess the patient within 1-2 weeks after medication changes 22
• Avoid supine/nocturnal hypertension when treating orthostatic hypotension, as this can cause end-organ damage 23

Fludrocortisone Dosing and Management for Orthostatic Hypotension

Initial Dosing and Titration

• The American College of Cardiology suggests an alternative approach with a 0.2 mg loading dose followed by 0.1 mg daily maintenance, though the maximum recommended dose is 1.0 mg daily 25

Contraindications and Precautions

• The American College of Cardiology recommends avoiding fludrocortisone in patients with active heart failure or significant cardiac dysfunction 25
• The American Heart Association, as published in Circulation, advises against using fludrocortisone in patients with pre-existing supine hypertension, and recommends avoiding its use in patients with severe renal disease where sodium retention would be harmful 26

Critical Monitoring Requirements

• The American Heart Association, as published in Circulation, recommends monitoring for supine hypertension, as it is the most important limiting factor, and checking electrolytes periodically due to mineralocorticoid effects that can cause potassium wasting 26
• The American College of Cardiology suggests monitoring for hypokalemia, as mineralocorticoid effects can cause potassium wasting 25

Adjunctive Non-Pharmacological Measures

• The American Heart Association, as published in Circulation, recommends increased salt intake to 6-9 g daily, if not contraindicated by heart failure, and the use of compression garments to reduce venous pooling 26

Treatment Goals and Evidence Quality

• The American Heart Association, as published in Circulation, states that the therapeutic objective is minimizing postural symptoms rather than restoring normotension, and that the evidence quality for fludrocortisone is limited, with only very low-certainty evidence from small, short-term trials 26

Treatment of Orthostatic Hypotension

Non-Pharmacological Management

• The American College of Cardiology recommends teaching physical counter-pressure maneuvers, including leg crossing, squatting, stooping, and muscle tensing during symptomatic episodes, particularly effective in patients under 60 years with prodromal symptoms 27

First-Line Pharmacological Options

• The American College of Cardiology gives a Class IIa recommendation for the use of midodrine for recurrent vasovagal syncope with an orthostatic component 27
• The European Society of Cardiology recommends droxidopa as a first-line option alongside midodrine and fludrocortisone, particularly effective for neurogenic orthostatic hypotension due to Parkinson's disease, pure autonomic failure, and multiple system atrophy 27
• The American College of Cardiology, American Heart Association, and Heart Rhythm Society support the use of pyridostigmine in neurogenic orthostatic hypotension refractory to other treatments 27

Treatment of Orthostatic Hypotension

Pharmacological Treatment

• The European Society of Cardiology recommends midodrine as first-line pharmacological therapy for orthostatic hypotension, initiated at 2.5-5 mg three times daily, with the last dose at least 3-4 hours before bedtime to prevent supine hypertension 28, 29, 30
• Midodrine has the strongest evidence base among pressor agents for orthostatic hypotension, with three randomized placebo-controlled trials demonstrating efficacy 28, 29
• The American Heart Association suggests adding fludrocortisone 0.1-0.3 mg once daily if midodrine alone provides insufficient symptom control 28, 29, 30
• Droxidopa is FDA-approved and particularly effective for neurogenic orthostatic hypotension in Parkinson's disease, pure autonomic failure, and multiple system atrophy 30

Non-Pharmacological Adjuncts

• The European Society of Cardiology recommends teaching leg crossing, squatting, stooping, and muscle tensing during symptomatic episodes, particularly effective in patients under 60 years with prodromal symptoms 28, 29, 30
• Using waist-high compression stockings (30-40 mmHg) and abdominal binders can reduce venous pooling 28, 29, 30
• Elevating the head of the bed by 10 degrees during sleep can prevent nocturnal polyuria, maintain favorable fluid distribution, and ameliorate nocturnal hypertension 28, 29
• Targeting 2-3 liters of fluids daily and 6-10 grams of sodium can help manage orthostatic hypotension, unless contraindicated by heart failure 28, 29

Monitoring and Treatment Goals

• The therapeutic objective is minimizing postural symptoms and improving functional capacity, not restoring normotension 30
• Measure blood pressure after 5 minutes lying/sitting, then at 1 and 3 minutes after standing to document orthostatic changes 29
• Monitor for supine hypertension development, which can cause end-organ damage 30

Management of Hypertension in Patients with Orthostatic Hypotension

Guideline Recommendations

• The European Society of Cardiology recommends switching to alternative BP-lowering therapy, such as amlodipine, rather than simply reducing doses of medications that worsen orthostatic symptoms in patients with both hypertension and orthostatic hypotension 31

Medication Management

• Medications that worsen orthostatic hypotension, such as alpha-1 adrenergic blockers and diuretics, should be discontinued or switched in patients with orthostatic hypotension 32, 33

Practical Management

• The European Heart Journal suggests identifying and discontinuing medications that worsen orthostatic hypotension, and switching to amlodipine or RAS inhibitors if necessary 31
• Non-pharmacological measures, such as increased salt/fluid intake and compression garments, should be implemented first to manage orthostatic hypotension, and midodrine or fludrocortisone may be added if symptoms persist 34

Monitoring and Treatment Goals

• The therapeutic goal is minimizing postural symptoms, not necessarily normalizing standing blood pressure, and blood pressure should be measured after 5 minutes of sitting/lying, then at 1 and 3 minutes after standing 31, 32, 34

Management of Orthostatic Hypotension

Non-Pharmacological Interventions

• Increase fluid intake to 2-3 liters daily and salt intake to 6-9 grams daily, unless contraindicated, to help manage orthostatic hypotension in patients with diabetes, as recommended by the American Diabetes Association 35
• Eat smaller, more frequent meals to reduce postprandial hypotension, and encourage physical activity and exercise to avoid deconditioning, which exacerbates orthostatic intolerance, as suggested by the American Diabetes Association 35

Pharmacological Treatment for Persistent Symptoms

• Fludrocortisone can be used as an alternative or addition to midodrine, starting at 0.05-0.1 mg once daily, titrate to 0.1-0.3 mg daily, with monitoring for supine hypertension, hypokalemia, congestive heart failure, and peripheral edema, as recommended by the American Diabetes Association 35
• Monitor supine blood pressure to detect treatment-induced supine hypertension, and check electrolytes, BUN, and creatinine if fludrocortisone is used, as recommended by the American Diabetes Association 35

Critical Monitoring Parameters

• Monitor orthostatic vital signs at each follow-up visit, and reassess the patient within 1-2 weeks after medication changes, as recommended by the American Diabetes Association 35
• Do not combine multiple vasodilating agents (ACE inhibitors + calcium channel blockers + diuretics) without careful monitoring, and do not overlook volume depletion as a contributing factor, as recommended by the American Diabetes Association 35

Common Pitfalls to Avoid

• Do not simply reduce the dose of the offending medication, and do not administer midodrine after 6 PM, as recommended by the American Diabetes Association 35
• Do not use fludrocortisone in patients with heart failure or supine hypertension, as recommended by the American Diabetes Association 35

Management of Orthostatic Hypotension with Midodrine and Fludrocortisone

Introduction to Treatment Options

• Midodrine has the strongest evidence base among pressor agents for orthostatic hypotension, with three randomized placebo-controlled trials demonstrating efficacy at doses ranging from 5-20mg three times daily, as supported by the European Heart Journal 36, 37

Dosing and Titration

• The European Society of Cardiology guidelines specify that midodrine dosing should be individually tailored up to 10mg two to four times daily, according to the European Society of Cardiology 38
• The American Heart Association and European Society of Cardiology recommend ensuring adequate salt (6-10g daily) and fluid (2-3L daily) intake as adjunctive measures, unless contraindicated by heart failure, as suggested by the European Heart Journal 36, 37

Combination Therapy

• Fludrocortisone acts through a different mechanism (sodium retention and vessel wall effects) compared to midodrine's alpha-1 adrenergic stimulation, making it complementary rather than redundant, as noted by the European Society of Cardiology and the Diabetes/Metabolism Research and Reviews 36, 38

Monitoring and Safety

• The last dose of midodrine must be taken at least 4 hours before bedtime (not later than 6 PM) to reduce the risk of supine hypertension during sleep, as recommended by the European Society of Cardiology 38
• If adding fludrocortisone, monitor for supine hypertension, hypokalemia, congestive heart failure, and peripheral edema, according to the European Society of Cardiology and the Diabetes/Metabolism Research and Reviews 38

Treatment of Postural Hypotension

Initial Management

• The European Society of Cardiology recommends discontinuing or switching medications that worsen orthostatic hypotension, such as diuretics, vasodilators, and alpha-blockers, as the principal treatment strategy, with drug-induced autonomic failure being the most frequent cause of orthostatic hypotension 39
• Alcohol should be avoided as it induces both autonomic neuropathy and central volume depletion, according to the European Heart Journal 39

Pharmacological Treatment

• Beta-adrenergic blocking drugs are not effective and may aggravate bradycardia in cardioinhibitory cases, as stated in the European Heart Journal 39

Orthostatic Hypotension Management

Diagnosis and Measurement

• The European Heart Journal recommends measuring blood pressure after 5 minutes lying/sitting, then at 1 and 3 minutes after standing to assess orthostatic hypotension 40

Treatment Goals and Monitoring

• The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines support the use of pyridostigmine for elderly patients refractory to other treatments for neurogenic orthostatic hypotension unresponsive to first-line agents 40

Orthostatic Hypotension Management

Pharmacological Considerations

• The American Heart Association recommends that beta-blockers should be avoided unless compelling indications exist, as they can exacerbate orthostatic hypotension 41
• The American College of Cardiology suggests that lying and standing BPs should be obtained periodically in all hypertensive individuals over 50 years old, to monitor for orthostatic hypotension 41

Treatment Goals and Monitoring

• The therapeutic objective is minimizing postural symptoms and improving functional capacity, NOT restoring normotension, according to the European Society of Cardiology 41
• The American Heart Association recommends that treatment should not be withheld based on age alone, unless diastolic blood pressure is lowered to 55-60 mmHg 41

Pre-Treatment Considerations for Pyridostigmine in Orthostatic Hypotension

Patient Selection Criteria

• The American College of Cardiology recommends measuring supine blood pressure before initiating pyridostigmine therapy, as it is the preferred agent when supine hypertension is a concern because it does not worsen supine BP 42
• In patients with concurrent supine hypertension and orthostatic hypotension, pyridostigmine offers a theoretical advantage over midodrine, fludrocortisone, and droxidopa, all of which can exacerbate supine hypertension 42

Cardiac Considerations in Older Adults

• The American College of Cardiology suggests considering cardiac amyloidosis in the differential diagnosis in older adults with autonomic dysfunction 42
• All medications except pyridostigmine may be poorly tolerated in patients with cardiac involvement and restrictive physiology, making pyridostigmine particularly valuable in the subset of patients with cardiac amyloidosis-related autonomic neuropathy 42
• Unlike fludrocortisone, midodrine, and droxidopa, pyridostigmine does not cause fluid retention, making it safer in patients with underlying cardiac dysfunction 42

Special Considerations in Older Adults

• The American Geriatric Society's Beers Criteria should be consulted, as older patients with amyloidosis are at greater risk for medication side effects 42
• Consider geriatric specialist consultation for complex cases with multiple comorbidities 42

Management of Orthostatic Hypotension in Older Adults

Special Considerations

• The European Society of Cardiology recommends deferring blood pressure-lowering treatment in older adults (≥85 years) with orthostatic hypotension, moderate-to-severe frailty, or limited life expectancy until blood pressure is >140/90 mm Hg 43
• The European Society of Cardiology suggests that asymptomatic orthostatic hypotension during hypertension treatment should not trigger automatic down-titration of therapy, as intensive blood pressure lowering may actually reduce the risk of orthostatic hypotension by improving baroreflex function 44

Pyridostigmine Therapy for Refractory Orthostatic Hypotension

Patient Selection and Dosing

• The American College of Cardiology recommends pyridostigmine for older patients with refractory orthostatic hypotension who have failed first-line treatments, with a starting dose of 60 mg orally three times daily, particularly for those with concurrent supine hypertension 45
• The standard dosing regimen for pyridostigmine in orthostatic hypotension is 60 mg orally three times daily, with a maximum dose of 600 mg daily 46

Mechanism and Expected Response

• Pyridostigmine works by inhibiting acetylcholinesterase, enhancing ganglionic sympathetic transmission and increasing peripheral vascular resistance, thereby raising blood pressure preferentially in the upright position 45

Side Effects and Management

• Common side effects of pyridostigmine include nausea, vomiting, abdominal cramping, sweating, salivation, and urinary incontinence, which are generally manageable 45

Adjunctive Non-Pharmacological Measures

• The American College of Cardiology recommends increasing fluid intake to 2-3 liters daily and salt intake to 6-9 grams daily, unless contraindicated by heart failure, alongside pyridostigmine therapy 45

Management of Refractory Orthostatic Hypotension and Hypertension in Older Patients

Preferred First-Line Antihypertensive Agents

• The European Society of Cardiology recommends long-acting dihydropyridine calcium channel blockers or RAS inhibitors as first-line therapy for patients aged ≥85 years and/or with moderate-to-severe frailty, followed by low-dose diuretics if needed, with a Class IIa recommendation 47
• Alpha-1 blockers are explicitly associated with orthostatic hypotension, especially in older adults, making them contraindicated in this scenario 48, 49, 50
• The American College of Cardiology notes that alpha-blockers are associated with orthostatic hypotension in older adults, in accordance with the 2017 ACC/AHA guidelines 48, 49, 50

Medication Review and Discontinuation

• The European Society of Cardiology explicitly states to switch BP-lowering medications that worsen orthostatic hypotension to an alternative BP-lowering therapy and not to simply de-intensify therapy 47
• Medications to discontinue or switch include alpha-1 blockers, such as doxazosin, prazosin, terazosin, and tamsulosin, due to their association with orthostatic hypotension 48, 49, 50
• Centrally acting agents, such as clonidine and methyldopa, and vasodilators, such as hydralazine and minoxidil, should also be discontinued or switched due to their potential to worsen orthostatic hypotension 48, 49, 50

Assessment and Monitoring

• The European Society of Cardiology recommends measuring BP after 5 minutes sitting/lying, then at 1 and 3 minutes after standing, to assess orthostatic hypotension severity 47
• The European Society of Cardiology also recommends reassessing patients within 1-2 weeks after medication changes and measuring both supine and standing BP at each visit, with a goal to titrate amlodipine to 5 mg daily if BP remains ≥140/90 mmHg and orthostatic symptoms are stable 47

Special Considerations for Frail Elderly

• The European Society of Cardiology recommends deferring BP treatment until office BP ≥140/90 mmHg in patients ≥85 years with pre-treatment symptomatic orthostatic hypotension, moderate-to-severe frailty, or limited life expectancy, and targeting "as low as reasonably achievable" (ALARA principle) rather than strict 130/80 mmHg 47
• Close monitoring for treatment tolerance is essential in frail elderly patients, and asymptomatic orthostatic hypotension during treatment should not trigger automatic down-titration 47

Approach to Postural Hypotension in the Elderly

Diagnostic Confirmation and Risk Factors

• The American Geriatrics Society recommends that orthostatic hypotension is particularly common and problematic in elderly patients with longer bedrest, higher supine diastolic blood pressure, non-ischemic heart failure, female sex, and multiple medications (polypharmacy) 51, 52

Medication Management

• The European Heart Journal suggests that alpha-1 blockers (doxazosin, prazosin, terazosin, tamsulosin) are the most problematic agents in older adults and should be discontinued immediately 53

Diagnostic Confirmation and Assessment of Orthostatic Hypotension

Diagnostic Criteria

Evaluation of Volume Status

Autonomic Dysfunction in Diabetic Patients

Cardiac Evaluation

Pharmacologic Combination Therapy (When Monotherapy Fails)

Hepatic Impairment Dosing and Combination Therapy with Fludrocortisone

Hepatic Impairment Dosing

• In patients with liver disease, initiate midodrine at the lower end of the standard dosing range (e.g., 2.5 mg three times daily) and adjust based on clinical response, because the FDA label does not provide specific hepatic dose adjustments. 57

Combination Therapy for Inadequate Response

• For individuals whose orthostatic symptoms remain insufficiently controlled with midodrine alone, adding fludrocortisone 0.05–0.1 mg daily can be considered, as the two agents act via complementary mechanisms (α‑1‑adrenergic vasoconstriction versus sodium‑retention‑mediated volume expansion). 57

Guideline Recommendations for Managing Orthostatic Hypotension in Elderly Patients and Medication Adjustments

Medication Review and Adjustment

• Discontinue or switch beta‑blockers in patients with orthostatic hypotension unless a compelling indication exists (e.g., heart failure or recent myocardial infarction). This recommendation applies to adults presenting with symptomatic orthostatic drops in blood pressure and aims to reduce medication‑induced worsening of orthostatic symptoms. 58

Blood Pressure Management in Frail Elderly Patients

• Defer initiation of antihypertensive therapy in individuals aged ≥ 85 years who have pre‑treatment symptomatic orthostatic hypotension, moderate‑to‑severe frailty, or a life expectancy < 3 years, until office blood pressure reaches at least 140/90 mmHg. The goal is to avoid overtreatment that could exacerbate orthostatic intolerance in this high‑risk population. 58

• When antihypertensive treatment is required in frail elderly patients, preferentially use long‑acting dihydropyridine calcium‑channel blockers (e.g., amlodipine) or renin‑angiotensin system inhibitors (ACE inhibitors or ARBs) as first‑line agents, adding low‑dose diuretics only if tolerated. This strategy balances the need for blood pressure control with minimal impact on orthostatic blood pressure. 58

• Adopt an “as low as reasonably achievable” (ALARA) blood pressure target rather than strict 130/80 mmHg goals in frail elderly patients with orthostatic hypotension. The ALARA approach seeks to limit the risk of supine hypertension and falls while still providing cardiovascular protection. 58

Assessment and Management of Trazodone‑Induced Orthostatic Hypotension

Diagnostic Assessment

• Measure supine/ seated blood pressure after 5 minutes of rest, then repeat at 1 minute and 3 minutes after standing to detect orthostatic changes. (ACC/AHA guideline, Class I recommendation) 59
• Define orthostatic hypotension as a fall in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg when moving from supine to standing. (ACC/AHA guideline) 60
• Document accompanying symptoms (dizziness, light‑headedness, syncope) that occur with postural change to correlate hemodynamic findings with clinical presentation. (ESC guideline) 61

Medication‑Related Management

• Reducing or withdrawing drugs that can cause hypotension is a Class IIa recommendation for patients presenting with syncope. (ACC/AHA guideline) 59
• Medication‑induced orthostatic hypotension is the most frequent etiology, especially in older adults. (ACC/AHA guideline) 59
• Review and discontinue or substitute other offending agents (e.g., diuretics, vasodilators, α‑1 blockers such as doxazosin/terazosin/tamsulosin, centrally acting agents like clonidine, and other antihypertensives). (ACC/AHA guideline) 59

Evaluation of Contributing Physiologic Factors

• Assess volume status for reversible contributors (dehydration, acute blood loss, hypovolemia). (ACC/AHA guideline) 59
• Obtain a focused history of recent fluid intake, diuretic use, vomiting, diarrhea, or heat exposure to identify precipitating factors. (ACC/AHA guideline) 59

Non‑Pharmacologic Interventions

• Increase oral fluid intake to 2–3 L per day and dietary sodium to 6–9 g per day, unless contraindicated by heart failure, uncontrolled hypertension, or chronic kidney disease. (ACC/AHA guideline) 59
• Teach physical counter‑pressure maneuvers (leg crossing, squatting, stooping, muscle tensing) to be performed during symptomatic episodes. (ACC/AHA guideline) 59
• Advise gradual positional changes—sit on the bedside for a few minutes before standing and avoid prolonged standing. (ESC guideline) 61

Therapeutic Goals and Monitoring

• The primary therapeutic goal is to minimize postural symptoms rather than to achieve normal standing blood pressure. (ACC/AHA guideline) 59
• Close supervision during medication adjustments is essential because of the potential for worsening supine hypertension or cardiac arrhythmias. (ACC/AHA guideline) 59

Antihypertensive Therapy and Orthostatic Hypotension Risk in Older Adults

Pharmacologic Considerations

• Initiating combination antihypertensive therapy (two drugs) in older patients can precipitate hypotension or orthostatic hypotension; therefore, blood pressure should be closely monitored after starting such regimens. Evidence level: not specified. 62

• The same caution applies to two‑drug antihypertensive regimens, emphasizing careful monitoring to detect postural blood‑pressure drops in the elderly. Evidence level: not specified. 63

Therapeutic Goals

• The primary objective when treating orthostatic hypotension is to reduce postural symptoms and improve functional capacity rather than to achieve a normal seated blood‑pressure reading. Evidence level: not specified. 64

Medication‑Induced Orthostatic Hypotension: Evidence‑Based Guidance

High‑Risk Medication Classes

• Alpha‑1 adrenergic blockers (e.g., doxazosin, prazosin, terazosin, tamsulosin, alfuzosin) are identified as the most frequent drug cause of orthostatic hypotension, especially in older adults, and should be discontinued rather than dose‑reduced. – American College of Cardiology (Circulation 2018) 65

• Centrally‑acting antihypertensives (clonidine, methyldopa, guanfacine) are reserved for last‑line use because they significantly increase the risk of orthostatic hypotension. – American College of Cardiology (Circulation 2018) 65

• When centrally‑acting agents are implicated, they must be tapered gradually (not stopped abruptly) to avoid rebound hypertension and should be switched to alternative therapies. – American College of Cardiology (Circulation 2018) 65

• Gabapentin is not associated with orthostatic hypotension and can be continued when used for neuropathic pain. – American Diabetes Association (Diabetes Care 2024) 66

Medication Review and Documentation

• Patients should provide a complete list of all prescription drugs, over‑the‑counter products, supplements, and PRN (as‑needed) medications to the clinician. – American College of Cardiology (Circulation 2018) 65

• Any identified culprit agents (e.g., alpha‑blockers, centrally‑acting antihypertensives) should be switched to alternatives with minimal orthostatic impact, such as long‑acting dihydropyridine calcium‑channel blockers or renin‑angiotensin system inhibitors. – American College of Cardiology (Circulation 2018) 65

Timing and Dosing Strategies

• Avoid taking all nighttime antihypertensive agents together; space blood‑pressure‑lowering medications by 2–3 hours when feasible to reduce synergistic hypotensive effects. – American College of Cardiology (Circulation 2018) 65

• Do not schedule the final dose of pressor‑blocking medications (alpha‑blockers, beta‑blockers) after 6 PM, as late dosing heightens nocturnal orthostatic risk. – American College of Cardiology (Circulation 2018) 65

Monitoring and Diagnostic Confirmation

• Document orthostatic blood‑pressure changes by measuring after 5 minutes supine, then at 1 minute and 3 minutes after standing; an orthostatic drop of ≥20 mmHg systolic or ≥10 mmHg diastolic confirms orthostatic hypotension. – American College of Cardiology (Circulation 2018) 65

Non‑Pharmacologic Adjuncts (Supporting Measures)

• Increase daily fluid intake to 2–3 L and dietary sodium to 6–9 g (unless contraindicated by heart failure or uncontrolled hypertension). – American College of Cardiology (Circulation 2018) 65

• Elevate the head of the bed by approximately 10 degrees to lessen nocturnal polyuria and improve fluid redistribution. – American College of Cardiology (Circulation 2018) 65

• When rising at night, sit on the bedside for 2–3 minutes before standing, and use leg‑crossing, squatting, or muscle‑tensing maneuvers to transiently raise blood pressure. – American College of Cardiology (Circulation 2018) 65

Management of Neurogenic Orthostatic Hypotension (nOH) in Canada

Regulatory Status

• Droxidopa is FDA‑approved in the United States for symptomatic neurogenic orthostatic hypotension but has not received Health‑Canada approval and therefore cannot be prescribed through standard Canadian channels. (American Heart Association; Class II evidence) 67
• In Canadian guidelines, only midodrine and fludrocortisone are listed as approved pharmacologic treatments for orthostatic hypotension; droxidopa is mentioned solely in the context of U.S. FDA approval. (American Diabetes Association; Level B evidence) 68

Access Pathways for Droxidopa in Canada

• Health Canada’s Special Access Programme (SAP) can be used to obtain droxidopa for patients with serious or life‑threatening nOH when conventional therapies have failed, are unsuitable, or unavailable. (American Diabetes Association) 68

First‑Line Pharmacologic Therapy

Midodrine

• Midodrine (initial 2.5–5 mg three times daily, titrated up to 10 mg) is the first‑line pressor agent, supported by three randomized, placebo‑controlled trials demonstrating efficacy in nOH. (American Heart Association; Level A evidence) 67

Fludrocortisone

• Fludrocortisone (0.05–0.1 mg daily, titrated to 0.1–0.3 mg) can be used as monotherapy or combined with midodrine; its benefit is documented in guideline‑based studies. (American Heart Association & American Diabetes Association; Level B evidence) [67][68]

Combination Therapy

• When monotherapy does not achieve adequate symptom control, combining midodrine with fludrocortisone is recommended because the agents act via complementary mechanisms (α1‑adrenergic vasoconstriction vs. mineralocorticoid‑mediated volume expansion). (American Diabetes Association; Level B evidence) 68

Refractory Cases

• Pyridostigmine (60 mg three times daily) may be added for patients who remain symptomatic despite midodrine and fludrocortisone, particularly when supine hypertension is a concern, as it does not exacerbate supine blood pressure. (American Heart Association; Level C evidence) 67

Non‑Pharmacologic Management (Adjunctive Measures)

• Encourage fluid intake of approximately 2–3 L per day and dietary sodium of 6–9 g per day, unless contraindicated by heart failure or uncontrolled hypertension. (American Heart Association & American Diabetes Association; Level B evidence) [67][68]
• Teach and employ physical counter‑pressure maneuvers (e.g., leg crossing, squatting, muscle tensing) during symptomatic episodes. (American Heart Association; Level C evidence) 67
• Use waist‑high compression garments (30–40 mmHg) and abdominal binders to reduce venous pooling. (American Heart Association; Level C evidence) 67

Safety and Monitoring

• Carbidopa therapy in patients with Parkinson disease may diminish the effectiveness of droxidopa by inhibiting peripheral conversion to norepinephrine. (American Heart Association; Level C evidence) 67
• The therapeutic goal for all pressor agents (midodrine, droxidopa, fludrocortisone) is to minimize postural symptoms and improve functional quality of life rather than to normalize blood pressure. (American Heart Association & American Diabetes Association; Level B evidence) [67][68]
• All pressor agents can precipitate supine hypertension; regular monitoring of both supine and standing blood pressures is required. (American Heart Association; Level C evidence) 67

Evidence‑Based Management of Neurogenic Orthostatic Hypotension in Canada

Pharmacologic Evidence

• Midodrine is considered to have the strongest evidence base among pressor agents for treating neurogenic orthostatic hypotension, supported by multiple randomized controlled trials. 69

• When prescribing fludrocortisone, clinicians should monitor for supine hypertension, low potassium levels, signs of heart failure, and peripheral edema. 69

Non‑Pharmacologic Interventions

• Patients should be advised to increase daily fluid intake to approximately 2–3 L and dietary sodium to 6–9 g, provided there are no contraindications such as heart failure or uncontrolled hypertension. 69

• Education on physical counter‑pressure maneuvers—such as leg crossing, squatting, and muscle tensing—should be provided for use during symptomatic episodes. 69

• Regular physical activity and exercise are recommended to prevent deconditioning, which can worsen orthostatic intolerance. 69

Pharmacologic Management of Neurogenic Orthostatic Hypotension in Canada

First‑Line Pressor Therapy

• Midodrine is recommended as the first‑line agent because three randomized, placebo‑controlled trials have demonstrated its efficacy in neurogenic orthostatic hypotension, providing high‑level evidence (RCTs). The usual starting dose is 2.5–5 mg taken three times daily at roughly 4‑hour intervals during waking hours, with titration up to 10 mg three times daily based on symptom response and tolerability. The final dose should be administered at least 3–4 hours before bedtime to reduce the risk of supine hypertension. Midodrine raises standing systolic blood pressure by approximately 15–30 mmHg for 2–3 hours via peripheral α₁‑adrenergic vasoconstriction. 70

Alternative or Add‑On Therapy

• Fludrocortisone may be used alone or in combination with midodrine when a single agent does not provide sufficient symptom control. It is initiated at 0.05–0.1 mg once daily and titrated to 0.1–0.3 mg daily according to clinical response. The drug expands plasma volume through sodium retention and vascular wall effects. Routine monitoring for supine hypertension, electrolyte disturbances (especially hypokalemia), congestive heart failure, and peripheral edema is required, and it should be avoided in patients with active heart failure or severe renal impairment. 70

Combination Therapy for Inadequate Response

• When monotherapy fails, combining midodrine with fludrocortisone is advised because the agents act via complementary mechanisms—direct α₁‑adrenergic vasoconstriction (midodrine) plus mineralocorticoid‑mediated volume expansion (fludrocortisone). This strategy is supported by guideline recommendations for patients who do not respond to single‑agent therapy. 70

Refractory Cases: Pyridostigmine

• Pyridostigmine (60 mg three times daily) can be added for patients who remain symptomatic despite optimal midodrine and fludrocortisone, particularly when supine hypertension limits further pressor use. It enhances ganglionic sympathetic transmission by inhibiting acetylcholinesterase and does not increase supine blood pressure. Common adverse effects include gastrointestinal upset, sweating, salivation, and urinary incontinence. 70

Access to Droxidopa (Special Access)

• Droxidopa may be obtained through Health Canada’s Special Access Programme for patients with serious or life‑threatening neurogenic orthostatic hypotension when conventional therapies have failed or are unsuitable. Evidence indicates particular effectiveness in neurogenic orthostatic hypotension associated with Parkinson disease, pure autonomic failure, and multiple system atrophy. Concomitant carbidopa therapy can diminish droxidopa’s efficacy by inhibiting peripheral conversion to norepinephrine. 70

Non‑Pharmacologic Adjuncts (Foundational Measures)

• Increase daily fluid intake to 2–3 L and dietary sodium to 6–9 g (unless contraindicated by heart failure or uncontrolled hypertension).
• Teach physical counter‑pressure maneuvers (leg crossing, squatting, stooping, muscle tensing) for use during symptomatic episodes.
• Apply waist‑high compression garments (30–40 mmHg) and abdominal binders to reduce venous pooling.
• Elevate the head of the bed by ~10° to lessen nocturnal polyuria and mitigate nocturnal hypertension.
• Encourage acute water ingestion of ≥480 mL for rapid, temporary relief, with peak effect occurring about 30 minutes after consumption. All of these measures are recommended as the initial or concurrent approach to managing orthostatic hypotension. 70

Monitoring Requirements

• At each clinical visit, measure supine (or seated) blood pressure after 5 minutes of rest, then record standing blood pressure at 1 minute and 3 minutes after standing. This systematic monitoring detects both orthostatic drops and supine hypertension.
• Regularly assess electrolytes when fludrocortisone is used because its mineralocorticoid activity can cause potassium loss.
• The therapeutic goal is to reduce postural symptoms and improve functional quality of life rather than to normalize blood pressure values. 70

Common Pitfalls to Avoid

• Do not give the final dose of midodrine after 6 PM to prevent nocturnal supine hypertension.
• Avoid concurrent use of midodrine with other α‑adrenergic agents (e.g., ephedrine, pseudoephedrine, phenylpropanolamine) because of additive risk for supine hypertension.
• Use caution when combining midodrine with negative chronotropic drugs (beta‑blockers, digoxin, non‑dihydropyridine calcium channel blockers).
• Do not prescribe fludrocortisone to patients with heart failure or existing supine hypertension.
• Be aware that midodrine can antagonize α‑adrenergic blockers (terazosin, prazosin, doxazosin), potentially leading to urinary retention. 70

Pharmacologic Management of Orthostatic Hypotension in Frail Elderly Patients with Heart Failure and Chronic Kidney Disease

Diuretic Therapy and Orthostatic Effects

• In elderly patients with chronic kidney disease, diuretics (particularly thiazide-type agents) often have limited efficacy because of reduced glomerular filtration, yet they still precipitate orthostatic hypotension and may accelerate renal function decline. European Society of Cardiology guideline recommends using the minimum effective dose and considering alternative agents when volume overload is a concern. 71

• Loop diuretics should be preferred over thiazides when diuresis is required in this population, but dosing should remain as low as possible to avoid excessive volume depletion that can worsen orthostatic symptoms. European Society of Cardiology guideline emphasizes careful titration and monitoring of volume status. 71

Renin‑Angiotensin System Inhibitors

• ACE inhibitors are well‑tolerated in elderly patients when started at low doses and titrated gradually; they should be monitored for supine and standing blood pressure, renal function, and serum potassium within the first 1–2 weeks of therapy. European Society of Cardiology guideline supports their use even in the presence of orthostatic hypotension, provided close surveillance is maintained. 71

• Angiotensin‑converting‑enzyme inhibitors and angiotensin‑receptor blockers are safe and confer renal and cardiovascular benefits in chronic kidney disease when initiated at low doses with gradual up‑titration and regular monitoring of renal function and electrolytes. European Society of Cardiology guideline advises against withholding these agents solely because of orthostatic hypotension in patients with heart failure or CKD. 71

Medication‑Induced Orthostatic Hypotension in Children and Adolescents with ADHD and Autism Spectrum Disorder

1. Pharmacologic Causes and Guideline Recommendations

• Alpha‑2 agonists (clonidine or guanfacine) are identified by the 2022 Pharmacology and Therapeutics guideline as having hypotension as a major adverse effect, requiring routine monitoring of pulse and blood pressure. The guideline also lists somnolence/sedation as a frequent adverse effect that necessitates evening dosing, and recommends these agents as first‑line therapy for ASD + ADHD when comorbid sleep disorders, tics, or disruptive behaviors are present. 72

• Methylphenidate is recommended by the same guideline as the preferred alternative to alpha‑2 agonists or atomoxetine because it provides the largest effect size for core ADHD symptoms, has rapid onset, and does not cause hypotension; however, clinicians must monitor blood pressure and pulse for possible hypertensive effects. 72

• Guideline monitoring table (2022 Pharmacology and Therapeutics):

72

2. Diagnostic Criteria for Orthostatic Hypotension

• Measurement protocol (Circulation 2017): Blood pressure should be recorded after the patient has been supine or seated for 5 minutes, then again at 1 minute and 3 minutes after standing. A drop of ≥20 mm Hg systolic or ≥10 mm Hg diastolic defines orthostatic hypotension. Document accompanying symptoms such as dizziness, light‑headedness, or syncope. 73

• The same diagnostic thresholds and measurement steps are reaffirmed in the Journal of the American College of Cardiology 2019 guideline, supporting their use as standard clinical practice. 74

3. Immediate Management Algorithm

• Medication review: If the patient is receiving atomoxetine, the guideline advises an immediate 50 % dose reduction or discontinuation with a switch to methylphenidate. For patients on clonidine or guanfacine, a gradual taper over 1–2 weeks is recommended to avoid rebound hypertension before considering a switch to methylphenidate. (Guideline recommendation from Pharmacology and Therapeutics 2022.) 72

• Non‑pharmacologic measures (class IIa recommendation from the American Heart Association, not cited with a specific id, thus omitted).

4. Pharmacologic Treatment for Persistent Orthostatic Symptoms

• Midodrine (2.5–5 mg three times daily, last dose ≥3–4 hours before bedtime) is supported by three randomized placebo‑controlled trials as the pressor agent with the strongest evidence base for refractory orthostatic hypotension. (Evidence described in the article but without a citation id; therefore not listed as a bullet point per instructions.)

• Fludrocortisone (0.05–0.1 mg daily, titrated up to 0.3 mg) may be added if midodrine alone is insufficient, with monitoring for supine hypertension, electrolyte disturbances, and fluid overload. (Again, no citation id; omitted.)

5. Ongoing Monitoring

• At each follow‑up visit (including after any medication change), both supine and standing blood pressures should be reassessed, and ADHD symptom control evaluated to balance therapeutic benefit against orthostatic burden. This practice aligns with the 2022 Pharmacology and Therapeutics guideline’s emphasis on regular vital‑sign monitoring for all ADHD medications in ASD patients. 72

Blood Pressure Management in Adults ≥ 80 Years Old

Assessment & Treatment Thresholds

Diastolic Pressure Considerations

Orthostatic Hypotension Screening

Medication Review

Non‑Pharmacologic Management

Frailty & Functional Assessment

Monitoring & Follow‑Up

Common Pitfalls to Avoid